FindTrial
Sign In

A Safety Study Of High-Dose Methotrexate Based On Real-World Data

A Safety Study Of High-Dose Methotrexate Based On Real-World Data

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500095694
Enrollment
Unknown
Registered
2025-01-10
Start date
2025-01-10
Completion date
Unknown
Last updated
2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematologic malignancies, Osteosarcoma

Interventions

Competitive Enrollment:None

Sponsors

Peking University Third Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1 Inpatients diagnosed with lymphoma ("primary central nervous system lymphoma", "B-cell lymphoma", "diffuse large B-cell lymphoma", "follicular cell lymphoma", "high-grade B-cell lymphoma", "Burkitt lymphoma", "T-cell lymphoma", "T-lymphoblastic lymphoma", "extranodal NK/T-cell lymphoma", etc.), leukemia ("acute lymphoblastic leukemia", etc.), osteosarcoma, and soft tissue sarcoma 2 Patients receiving high-dose methotrexate (dose =500mg/m2)

Exclusion criteria

Exclusion criteria: 1 Patients who lack blood routine and biochemical examination after HDMTX chemotherapy 2 Patients who lack MTX blood concentration results after HDMTX chemotherapy

Design outcomes

Primary

MeasureTime frame
Hepatic Insufficiency;Acute Kidney Injury;Myelosuppression;Delayed Methotrexate Clearance;—

Countries

China

Contacts

Public ContactZhao Rongsheng

Peking University Third Hospital

zhaorongsheng@bjmu.edu.cn+86 139 1098 9410

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026